Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Роль стресса и нарушений сна в развитии сердечно- сосудистых осложнений у пациентов с артериальной гипертензией: что важно знать интернисту?
Роль стресса и нарушений сна в развитии сердечно- сосудистых осложнений у пациентов с артериальной гипертензией: что важно знать интернисту?
Ионин В.А. Роль стресса и нарушений сна в развитии сердечно-сосудистых осложнений у пациентов с артериальной гипертензией: что важно знать интернисту? Consilium Medicum. 2023;25(1):15–19.
DOI: 10.26442/20751753.2023.1.202133
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
DOI: 10.26442/20751753.2023.1.202133
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В данной публикации обсуждаются механизмы, лежащие в основе развития артериальной гипертензии на фоне стресса, рассмотрены актуальные проблемы контроля артериального давления у пациентов со стресс-индуцированными нарушениями сна, клинические особенности пациентов с гиперсимпатикотонией как главным механизмом развития артериальной гипертензии и вариабельности артериального давления у пациентов с коморбидной патологией, алгоритм диагностики, а также представлены современные рекомендации в стратегии выбора оптимальной антигипертензивной терапии с возможностью персонализированного выбора в различных клинических ситуациях.
Ключевые слова: стресс, нарушения сна, артериальная гипертензия, антигипертензивная терапия
Keywords: stress, sleep disorders, arterial hypertension, antihypertensive therapy
Ключевые слова: стресс, нарушения сна, артериальная гипертензия, антигипертензивная терапия
________________________________________________
Keywords: stress, sleep disorders, arterial hypertension, antihypertensive therapy
Полный текст
Список литературы
1. Kotseva K, de Backer G, de Bacquer D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26:824-35.
2. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347-60.
3. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13.
4. Karmali KN, Persell SD, Perel P, et al. Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017;3. DOI:10.1002/14651858.CD006887.PUB4
5. Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol. 2018;15:215-29.
6. Rozanski A. Behavioral cardiology: current advances and future directions. J Am Coll Cardiol. 2014;64:100-10.
7. Albus C, Waller C, Fritzsche K, et al. Significance of psychosocial factors in cardiology: update. 2018: Position paper of the German Cardiac Society. Clin Res Cardiol. 2019;108:1175-96.
8. Schultz WM, Kelli HM, Lisko JC, et al. Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions. Circulation. 2018;137:2166-78.
9. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-337.
10. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109:685-92.
11. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for themanagement of arterial hypertension. Eur Heart J. 2018;39:3021-104.
12. Seravalle G, Facchetti R, Cappellini C, et al. Elevated heart rate as sympathetic biomarker in human obesity. Nutr Metab Cardiovasc Dis. 2022;32. DOI:10.1016/J.NUMECD.2022.07.011
13. Fatani BZ, Al-Yahyawi H, Raggam AA, et al. Perceived stress and willingness to quit smoking among patients with depressive and anxiety disorders seeking treatment. Health Sci Rep. 2022;5. DOI:10.1002/HSR2.503
14. Leone A. Smoking and hypertension: independent or additive effects to determining vascular damage? Curr Vasc Pharmacol. 2011;9:585-93.
15. Hering D, Kucharska W, Kara T, et al. Smoking is associated with chronic sympathetic activation in hypertension. Blood Press. 2010;19:152-5.
16. Prichard BNC. The use of moxonidine in the treatment of hypertension. J Hypertens. 1997;15. DOI:10.1097/00004872-199715011-00007
17. Karlafti EF, Hatzitolios AI, Karlaftis AF, et al. Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection. J Pharm Bioallied Sci. 2013;5:253-6.
18. Бойцов С.А., Баланова Ю.А., Шальнова С.А., и др. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;13(4):4-14 [Boytsov SA, Balanova YuA, Shalnova SA, et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14 (in Russian)].
19. Sanjuliani AF, de Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract. 2006;60:621-9.
20. Karlafti EF, Hatzitolios AI, Karlaftis AF, et al. Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection. J Pharm Bioallied Sci. 2013;5:253-6.
21. Li M, Zhang XW, Hou WS, Tang ZY. Insomnia and risk of cardiovascular disease: a meta-analysis of cohort studies. Int J Cardiol. 2014;176:1044-7.
22. Cappuccio FP, D’Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep. 2010;33:585-92.
23. Magee CA, Kritharides L, Attia J, et al. Short and long sleep duration are associated with prevalent cardiovascular disease in Australian adults. J Sleep Res. 2012;21:441-7.
24. Lo K, Woo B, Wong M, Tam W. Subjective sleep quality, blood pressure, and hypertension: a meta-analysis. J Clin Hypertens. 2018;20:592.
25. Mansoor GA, White WB, McCabe EJ, Giacco S. The relationship of electronically monitored physical activity to blood pressure, heart rate, and the circadian blood pressure profile. Am J Hypertens. 2000;13:262-7.
26. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540-5.
27. Hsieh CG, Martin JL. Short Sleep, Insomnia, and Cardiovascular Disease. Curr Sleep Med Rep. 2019;5:234.
28. Ernsberger P, Graves ME, Graff LM, et al. I1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann N Y Acad Sci. 1995;763:22-42.
29. Переверзев А. Оригинальные и воспроизведенные лекарственные средства: действительно ли они сопоставимы? Акцент на моксонидин. РМЖ. 2021;29(9):6-10 [Pereverzev AP. Original and reproduced medicinal products: are they comparable? Emphasis on moxonidine. RMJ. 2021;9:6-10 (in Russian)].
2. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347-60.
3. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13.
4. Karmali KN, Persell SD, Perel P, et al. Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017;3. DOI:10.1002/14651858.CD006887.PUB4
5. Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol. 2018;15:215-29.
6. Rozanski A. Behavioral cardiology: current advances and future directions. J Am Coll Cardiol. 2014;64:100-10.
7. Albus C, Waller C, Fritzsche K, et al. Significance of psychosocial factors in cardiology: update. 2018: Position paper of the German Cardiac Society. Clin Res Cardiol. 2019;108:1175-96.
8. Schultz WM, Kelli HM, Lisko JC, et al. Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions. Circulation. 2018;137:2166-78.
9. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-337.
10. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109:685-92.
11. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for themanagement of arterial hypertension. Eur Heart J. 2018;39:3021-104.
12. Seravalle G, Facchetti R, Cappellini C, et al. Elevated heart rate as sympathetic biomarker in human obesity. Nutr Metab Cardiovasc Dis. 2022;32. DOI:10.1016/J.NUMECD.2022.07.011
13. Fatani BZ, Al-Yahyawi H, Raggam AA, et al. Perceived stress and willingness to quit smoking among patients with depressive and anxiety disorders seeking treatment. Health Sci Rep. 2022;5. DOI:10.1002/HSR2.503
14. Leone A. Smoking and hypertension: independent or additive effects to determining vascular damage? Curr Vasc Pharmacol. 2011;9:585-93.
15. Hering D, Kucharska W, Kara T, et al. Smoking is associated with chronic sympathetic activation in hypertension. Blood Press. 2010;19:152-5.
16. Prichard BNC. The use of moxonidine in the treatment of hypertension. J Hypertens. 1997;15. DOI:10.1097/00004872-199715011-00007
17. Karlafti EF, Hatzitolios AI, Karlaftis AF, et al. Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection. J Pharm Bioallied Sci. 2013;5:253-6.
18. Boytsov SA, Balanova YuA, Shalnova SA, et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14 (in Russian).
19. Sanjuliani AF, de Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract. 2006;60:621-9.
20. Karlafti EF, Hatzitolios AI, Karlaftis AF, et al. Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection. J Pharm Bioallied Sci. 2013;5:253-6.
21. Li M, Zhang XW, Hou WS, Tang ZY. Insomnia and risk of cardiovascular disease: a meta-analysis of cohort studies. Int J Cardiol. 2014;176:1044-7.
22. Cappuccio FP, D’Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep. 2010;33:585-92.
23. Magee CA, Kritharides L, Attia J, et al. Short and long sleep duration are associated with prevalent cardiovascular disease in Australian adults. J Sleep Res. 2012;21:441-7.
24. Lo K, Woo B, Wong M, Tam W. Subjective sleep quality, blood pressure, and hypertension: a meta-analysis. J Clin Hypertens. 2018;20:592.
25. Mansoor GA, White WB, McCabe EJ, Giacco S. The relationship of electronically monitored physical activity to blood pressure, heart rate, and the circadian blood pressure profile. Am J Hypertens. 2000;13:262-7.
26. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540-5.
27. Hsieh CG, Martin JL. Short Sleep, Insomnia, and Cardiovascular Disease. Curr Sleep Med Rep. 2019;5:234.
28. Ernsberger P, Graves ME, Graff LM, et al. I1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann N Y Acad Sci. 1995;763:22-42.
29. Pereverzev AP. Original and reproduced medicinal products: are they comparable? Emphasis on moxonidine. RMJ. 2021;9:6-10 (in Russian).
2. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347-60.
3. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13.
4. Karmali KN, Persell SD, Perel P, et al. Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017;3. DOI:10.1002/14651858.CD006887.PUB4
5. Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol. 2018;15:215-29.
6. Rozanski A. Behavioral cardiology: current advances and future directions. J Am Coll Cardiol. 2014;64:100-10.
7. Albus C, Waller C, Fritzsche K, et al. Significance of psychosocial factors in cardiology: update. 2018: Position paper of the German Cardiac Society. Clin Res Cardiol. 2019;108:1175-96.
8. Schultz WM, Kelli HM, Lisko JC, et al. Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions. Circulation. 2018;137:2166-78.
9. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-337.
10. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109:685-92.
11. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for themanagement of arterial hypertension. Eur Heart J. 2018;39:3021-104.
12. Seravalle G, Facchetti R, Cappellini C, et al. Elevated heart rate as sympathetic biomarker in human obesity. Nutr Metab Cardiovasc Dis. 2022;32. DOI:10.1016/J.NUMECD.2022.07.011
13. Fatani BZ, Al-Yahyawi H, Raggam AA, et al. Perceived stress and willingness to quit smoking among patients with depressive and anxiety disorders seeking treatment. Health Sci Rep. 2022;5. DOI:10.1002/HSR2.503
14. Leone A. Smoking and hypertension: independent or additive effects to determining vascular damage? Curr Vasc Pharmacol. 2011;9:585-93.
15. Hering D, Kucharska W, Kara T, et al. Smoking is associated with chronic sympathetic activation in hypertension. Blood Press. 2010;19:152-5.
16. Prichard BNC. The use of moxonidine in the treatment of hypertension. J Hypertens. 1997;15. DOI:10.1097/00004872-199715011-00007
17. Karlafti EF, Hatzitolios AI, Karlaftis AF, et al. Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection. J Pharm Bioallied Sci. 2013;5:253-6.
18. Бойцов С.А., Баланова Ю.А., Шальнова С.А., и др. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;13(4):4-14 [Boytsov SA, Balanova YuA, Shalnova SA, et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14 (in Russian)].
19. Sanjuliani AF, de Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract. 2006;60:621-9.
20. Karlafti EF, Hatzitolios AI, Karlaftis AF, et al. Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection. J Pharm Bioallied Sci. 2013;5:253-6.
21. Li M, Zhang XW, Hou WS, Tang ZY. Insomnia and risk of cardiovascular disease: a meta-analysis of cohort studies. Int J Cardiol. 2014;176:1044-7.
22. Cappuccio FP, D’Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep. 2010;33:585-92.
23. Magee CA, Kritharides L, Attia J, et al. Short and long sleep duration are associated with prevalent cardiovascular disease in Australian adults. J Sleep Res. 2012;21:441-7.
24. Lo K, Woo B, Wong M, Tam W. Subjective sleep quality, blood pressure, and hypertension: a meta-analysis. J Clin Hypertens. 2018;20:592.
25. Mansoor GA, White WB, McCabe EJ, Giacco S. The relationship of electronically monitored physical activity to blood pressure, heart rate, and the circadian blood pressure profile. Am J Hypertens. 2000;13:262-7.
26. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540-5.
27. Hsieh CG, Martin JL. Short Sleep, Insomnia, and Cardiovascular Disease. Curr Sleep Med Rep. 2019;5:234.
28. Ernsberger P, Graves ME, Graff LM, et al. I1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann N Y Acad Sci. 1995;763:22-42.
29. Переверзев А. Оригинальные и воспроизведенные лекарственные средства: действительно ли они сопоставимы? Акцент на моксонидин. РМЖ. 2021;29(9):6-10 [Pereverzev AP. Original and reproduced medicinal products: are they comparable? Emphasis on moxonidine. RMJ. 2021;9:6-10 (in Russian)].
________________________________________________
2. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347-60.
3. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13.
4. Karmali KN, Persell SD, Perel P, et al. Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017;3. DOI:10.1002/14651858.CD006887.PUB4
5. Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol. 2018;15:215-29.
6. Rozanski A. Behavioral cardiology: current advances and future directions. J Am Coll Cardiol. 2014;64:100-10.
7. Albus C, Waller C, Fritzsche K, et al. Significance of psychosocial factors in cardiology: update. 2018: Position paper of the German Cardiac Society. Clin Res Cardiol. 2019;108:1175-96.
8. Schultz WM, Kelli HM, Lisko JC, et al. Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions. Circulation. 2018;137:2166-78.
9. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-337.
10. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109:685-92.
11. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for themanagement of arterial hypertension. Eur Heart J. 2018;39:3021-104.
12. Seravalle G, Facchetti R, Cappellini C, et al. Elevated heart rate as sympathetic biomarker in human obesity. Nutr Metab Cardiovasc Dis. 2022;32. DOI:10.1016/J.NUMECD.2022.07.011
13. Fatani BZ, Al-Yahyawi H, Raggam AA, et al. Perceived stress and willingness to quit smoking among patients with depressive and anxiety disorders seeking treatment. Health Sci Rep. 2022;5. DOI:10.1002/HSR2.503
14. Leone A. Smoking and hypertension: independent or additive effects to determining vascular damage? Curr Vasc Pharmacol. 2011;9:585-93.
15. Hering D, Kucharska W, Kara T, et al. Smoking is associated with chronic sympathetic activation in hypertension. Blood Press. 2010;19:152-5.
16. Prichard BNC. The use of moxonidine in the treatment of hypertension. J Hypertens. 1997;15. DOI:10.1097/00004872-199715011-00007
17. Karlafti EF, Hatzitolios AI, Karlaftis AF, et al. Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection. J Pharm Bioallied Sci. 2013;5:253-6.
18. Boytsov SA, Balanova YuA, Shalnova SA, et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14 (in Russian).
19. Sanjuliani AF, de Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract. 2006;60:621-9.
20. Karlafti EF, Hatzitolios AI, Karlaftis AF, et al. Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection. J Pharm Bioallied Sci. 2013;5:253-6.
21. Li M, Zhang XW, Hou WS, Tang ZY. Insomnia and risk of cardiovascular disease: a meta-analysis of cohort studies. Int J Cardiol. 2014;176:1044-7.
22. Cappuccio FP, D’Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep. 2010;33:585-92.
23. Magee CA, Kritharides L, Attia J, et al. Short and long sleep duration are associated with prevalent cardiovascular disease in Australian adults. J Sleep Res. 2012;21:441-7.
24. Lo K, Woo B, Wong M, Tam W. Subjective sleep quality, blood pressure, and hypertension: a meta-analysis. J Clin Hypertens. 2018;20:592.
25. Mansoor GA, White WB, McCabe EJ, Giacco S. The relationship of electronically monitored physical activity to blood pressure, heart rate, and the circadian blood pressure profile. Am J Hypertens. 2000;13:262-7.
26. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540-5.
27. Hsieh CG, Martin JL. Short Sleep, Insomnia, and Cardiovascular Disease. Curr Sleep Med Rep. 2019;5:234.
28. Ernsberger P, Graves ME, Graff LM, et al. I1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann N Y Acad Sci. 1995;763:22-42.
29. Pereverzev AP. Original and reproduced medicinal products: are they comparable? Emphasis on moxonidine. RMJ. 2021;9:6-10 (in Russian).
Авторы
В.А. Ионин*
ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, Санкт-Петербург, Россия
*ionin.v.a@gmail.com
Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia
*ionin.v.a@gmail.com
ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, Санкт-Петербург, Россия
*ionin.v.a@gmail.com
________________________________________________
Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia
*ionin.v.a@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.